enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Ozempic Is Part of New Stroke Prevention Guidelines ... - AOL

   www.aol.com/ozempic-part-stroke-prevention...

   More than 795,000 people in the U.S. have a stroke each year, which is a leading cause of serious long-term disability. Many of the leading risk factors for stroke are modifiable, making ...

3. More middle-aged adults have been dying from strokes ... - AOL

   www.aol.com/lifestyle/more-middle-aged-adults...

   In recent years, more adults between the ages of 45 and 64 have been dying from strokes, according to a new report from the Centers for Disease Control and Prevention (CDC). Stroke occurs when ...

4. Drugs like Ozempic may help lower 2nd stroke, heart attack risk

   www.aol.com/drugs-ozempic-may-help-lower...

   A new study says that type 2 diabetes medications GLP-1 agonists and SGLT2 inhibitors may help lower a stroke survivor’s risk of experiencing a subsequent stroke, heart attack, or death ...

5. Antihypertensive - Wikipedia

   en.wikipedia.org/wiki/Antihypertensive

   Anti-hypertensive drugs in older people The latest evidence does not have evidence of an effect due to discontinuing vs continuing medications used for treating elevated blood pressure or prevention of heart disease in older adults on all-case mortality and incidence of heart attack. [ 75 ]

6. Dipyridamole - Wikipedia

   en.wikipedia.org/wiki/Dipyridamole

   A combination of dipyridamole and aspirin (acetylsalicylic acid/dipyridamole) is FDA-approved for the secondary prevention of stroke and has a bleeding risk equal to that of aspirin use alone. [3] Dipyridamole absorption is pH -dependent and concomitant treatment with gastric acid suppressors (such as a proton pump inhibitor ) will inhibit the ...

7. Dabigatran - Wikipedia

   en.wikipedia.org/wiki/Dabigatran

   Dabigatran is used to prevent strokes in those with atrial fibrillation not caused by heart valve issues, as well as deep vein thrombosis and pulmonary embolism in persons who have been treated for 5–10 days with parenteral anticoagulant (usually low molecular weight heparin), and to prevent deep vein thrombosis and pulmonary embolism in some circumstances.